Patent applications published 16 June 2010

Published: 15-Jul-2010
Patient Experience

Selected patent applications from the weekly European Patents Bulletin


  • Method of treating glaucoma using rasagiline
    Teva Pharmaceutical Industries 2194780*

  • Compsna and methods for enhancing cognitive function
    Nestec 2192781*

  • Methods for promoting wound healing and muscle regeneration with the cell signalling protein NELL1
    UT-Batelle 2194782*

  • Compsns and methods for apoptosis modulators
    VM Discovery 2194783*

  • Non-aqueous pharmaceutical compsns
    Archimedes Development 2194965*

  • Aerosols for sinunasal drug delivery
    PARI Pharma 2194966*

  • Local topical administration formulations containing fipronil
    Intervet International 2194967*

  • Flavoured clay-based therapeutic compsn
    Ipsen Pharma 2194968*

  • Acid-containing lipid formulations
    Camurus 2194969*

  • Enhancement of the efficacy of therapeutic proteins
    The North West University 2194970*

  • Pharmaceutical powder compsns comprising a benziozodiazepine drug and chitosan
    Archimedes Development 2194971*

  • Mixed metal compounds used as antacids
    Ineos Healthcare 2194972*

  • Dip coated compsns containing copolymer of polyvinyl alcohol and polyethylene glycol and a gum
    McNeil-PPC 2194973*

  • Antibacterial pyrocatechols and related methods
    Colgate-Palmolive 2194974*

  • Methods of inhibiting the formation of amyloid-beta diffusible ligands using a acylhydrazide compounds
    Acumen Pharmaceuticals 2194975*

  • Hepatitis C antiviral compsns and methods
    Biotron 2194976*

  • Method of preventing nephrocalcinosis
    CB Fleet Company 2194977*

  • Use of gestagens in combination with (6S)-5-methyltetrahydrofolate for the therapy of endometriosis with simultaneous reduction of therapy side-effects and the reduction of the risk of congenital malformations in case of pregnancy
    Bayer Schering Pharma Aktiengesellschaft 2194978*

  • Treatment of CNS and pain disorders
    Copharm 2194979*

  • Fluoro-containing derivatives of hydrogenated pyrido-4,3-B-indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
    D2e 2194980*

  • Bismenzimidazoles as antimalarial agents
    Université de Mons-Hainaut 2194981*

  • Compounds which have activity at M1 receptor and their uses in medicine
    Glaxo Group 2194982*

  • Compounds which have activity at M1 receptor and their uses in medicine
    Glaxo Group 2194983*

  • Medicament for treating or preventing proteinuria
    Medice Arzneimittel Pütter 2194984*

  • Antimalarial compounds with flexible side-chains
    Medicines for Malaria Venture 2194985*

  • 3,4-dihydro-1,4-benzoxazine, 3,4-dihydro-1,4-benzothiazine and 1,2,3,4-tatrahydro-quinoxaline derivatives as alpha-2C adrenoreceptor agonists
    Schering; Pharmacopeia 2194986*

  • Novel stat3 pathway inhibitors and cancer stem cell inhibitors
    Boston Biomedical 2194987*

  • Piperidinylamino-thieno[2,3-D]pyrimidine compounds for treating fibrosis
    Epix Delaware 2194988*

  • Methods of treating or preventing respiratory tract infection comprising administering cholecalciferol
    Procter & Gamble 2194989*

  • Method for providing energy, relieving stress and mood enhancing benefits comprising administering a compsn comprising cholecalciderol and a tea extract
    Procter & Gamble 2194990*

  • Compsns comprising lipoteichoic acid for use in treating pleural effusion or pneumothorax
    ISIS Innovation 2194991*

  • Epidermal stimulation to enhance hair follicle formation
    Intercytex 2194992*

  • Non-invasive in vivo imaging and methods for treating type 1 diabetes
    Biocrine 2194993*

  • Cocoa extract for use in providing skin benefits
    Barry Callebaut 2194994*

  • Tryptase inhibiting mustard extract
    DSM IP Assets 2194995*

  • Compsn and methods for treating inflammation and inflammation-related disorders by Plectranthus ambionicus extracts
    Academia Sinica 2194996*

  • Oestrogenic extracts of Rheum plantum L of the Polygonaceae family and uses thereof
    Bionovo 2194997*

  • Oestrogenic extracts of Asparagus conchinchinensis (lour.) merr of the Liliaceae family and uses thereof
    Bionovo 2194998*

  • Oestrogenic extracts of Astragalus membranaceus Fisch.Bge.var. mongolicus BGE of the Leguminosae family and uses thereof
    Bionovo 2194999*

  • Sprayable compsn containing red vine leaf extract
    Boehringer Ingelheim International 2195000*

  • Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs and adenovirus to tissues and cells, and compsns and kits
    Tufts University 2195001*

  • Erythropoietin receptor peptide formulations and uses
    Affymax 2195002*

  • Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
    Oncotherapy Science 2195003*

  • Method of inhibiting Clostridium difficile by adminstration of oritavancin
    Targanta Therapeutics; University of Leeds 2195004*

  • Gene signature for the prediction of radiation therapy response
    University of South Florida 2195005*

  • Use of a peptide and an analgesic pharmaceutical agent
    Lipkowski, Andrzej; Carr, Daniel; Misicka-Kesik, Aleksandra; Kosson, Piotr; Klinowiecka, Anna 2195006*

  • Use of sco-spondin peptides for inhibiting or preventing neuronal apoptosis mediated by cell death receptor ligands
    Institut National de la Sante et de la Recherche Medicale (INSERM) 2195007*

  • Use of copolymer 1 for treatment of muscular dystrophy
    Hadasit Medical Research Services & development 2195008*

  • Cyclic undecapeptides and derivatives as mutiple sclerosis therapies
    Oregon Health and Science University; The Government of the United States of America D.B.A. Department of Veterans Affairs 2195009*

  • Treatment with kallikrein inhibitors
    Genzyme 2195010*

  • Treatment with kallikrein inhibitors
    Genzyme 2195011*

  • Use of a peptide as a therapeutic agent
    Mondobiotech Laboratories 2195012*

  • Therapeutic use of a growth factor, metRNL
    NcGene 2195013*

  • Use of G-CNF for the treatment for stroke
    Sygnis Bioscience 2195014*

  • Compsn for treating prostate cancer (PCa)
    Curevac 2195015*

  • Vaccine for the treatment of osteoarthritis
    Intervet International 2195016*

  • Human antibodies that bind mesothelin and uses thereof
    Bristol-Myers Squibb 2195017*

  • Novel polysaccharide immunogens from Clostridium difficile
    University of Guelph 2195018*

  • Method of eliciting an immune response against pandemic influenza virus
    CSL 2195019*

  • Inactivated influenza virus
    Nobilon International 2195020*

  • Compsn comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
    ImmunoVaccine Technologies 219022*

  • Humanised anti-CXCR5 antibodies, derivatives thereof and their uses
    Sanofi-Aventis 2195023*

  • Method of inhibiting complement activation with factor BB specific antibodies
    NovelMed Therapeutics 2195024*

  • Therapeutic antibody purification method and method of use
    CSL 2195025*

See more

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

Read more
The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape

Trending Articles

  1. Pfizer wins battle over Viagra trademark Energy drinks brand Viaguara cannot be registered as an EU trademark
  2. Patent applications published 7 July 2010 Selected patent applications from the weekly European Patents Bulletin
  3. Genmab says GSK has settled patent case with Genentech Concerning two US patents for ofatumumbab
  4. Boehringer Ingelheim suffers Spiriva patent blow in India Indian patent office has revoked a patent granted for tiotropium bromide monohydrate under the Spiriva brand, paving the way for Cipla to continue selling its generic version in the Indian market
  5. Phillips-Medisize acquires mini-tablet dispenser patent The US company has acquired exclusive ownership of the patent from a global pharmaceutical company and expects to make the product available by early 2020

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape
Regulatory

Pharmaseal reaches milestone in crowdfunding campaign

The company was first founded in 2016
Patient Experience

Ilya Pharma awarded engineered lactic acid bacterial strain patent

The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
Pharmaceutical

A card in the competition for COVID-19 drug supply

The patent system has come under pressure both politically and, more recently, as pharma companies scale-up their operations to make large amounts of drugs available to treat COVID-19, reports Paul England, Senior Professional Support Lawyer at Taylor Wessing
Ingredients

Sigrid Therapeutics obtains US patent for silica-based biomaterial SiPore15 for the treatment and prevention of obesity

Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes
Ingredients

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

The drug for treatment of multiple CNS conditions will be reformed into a novel patentable form to potentially improve delivery and give more intellectual property protection
Digital

Documentation complexity at crisis point?

Do we focus too much on the paperwork, to the detriment of product and patients? Has documentation become so complex it’s become a dangerous distraction and your biggest risk? by Martin Lush
Subscribe now